Migraine Treatment and Insurance Coverage in India

This is a reference overview for a treating physician or hospital administrator assessing what's realistically reimbursable, not insurance advice for an individual patient. It covers where PMJAY and private OPD riders actually apply, why CGRP drugs sit outside most policies, and the pre-existing-disease rule that trips up migraine patients specifically.

Does Ayushman Bharat PM-JAY cover migraine treatment?

PM-JAY is a hospitalisation-based scheme covering secondary and tertiary inpatient care across roughly 1,900 procedure packages, including neurology and neurosurgery, but routine outpatient migraine management, consultations, oral prophylaxis, triptans, doesn't fall under a hospitalisation package at all.

A migraine patient admitted for status migrainosus or for a neurology procedure genuinely requiring hospitalisation can access relevant packages under the current Health Benefit Package 2.2 list maintained by the National Health Authority. The everyday reality, monthly prophylactic medication and specialist consultation, sits outside what PM-JAY was designed to reimburse.

Why doesn't standard private health insurance cover migraine drugs either?

Most Indian private health insurance policies are indemnity products triggered by hospitalisation of 24 hours or more; a migraine consultation and prescription refill doesn't meet that trigger regardless of how debilitating the condition is. OPD cover exists but is typically a separate, lower-value add-on rider, not a default inclusion.

Where an OPD rider is purchased, it typically caps annual outpatient reimbursement at a modest fixed amount, per IRDAI's public guidance on health insurance regulations, which is rarely enough to cover a full year of a newer prophylactic drug class at current pricing.

What does the pre-existing disease rule mean for a migraine patient buying insurance?

Under IRDAI's current framework, insurers can classify a condition as pre-existing if it was diagnosed or treated within the 36 months before the policy was purchased, down from the earlier 48-month look-back, and pre-existing conditions carry a waiting period, up to 36 months in many current policies, before related claims are payable.

A patient with a documented migraine diagnosis who switches insurers, or buys a fresh migraine insurance policy after a gap, can face this waiting period specifically on migraine-related claims even while other conditions are covered from day one. This is a genuine access barrier that a treating neurologist should be aware exists when a patient asks why a claim was denied.

Why are CGRP monoclonal antibodies and gepants such a coverage problem specifically?

CGRP-pathway drugs, monoclonal antibodies like erenumab and galcanezumab for prevention, and gepants for acute or preventive use, are newer and priced well above the older triptan and NSAID classes Indian insurance products were designed around. Access remains limited because of cost, rollout stage, and the absence of routine coverage for an outpatient prophylactic, per a 2025 review of India's migraine treatment landscape in Neurology India.

This isn't a temporary gap that will close on its own. Insurance products are built around existing drug-cost norms, and a genuinely new therapeutic class at several multiples the cost of an older one takes years to work its way into standard OPD riders, if it ever does at the individual-policy level.

What does India's actual migraine treatment mix look like right now?

The most commonly used acute medications in Indian practice remain naproxen, often combined with domperidone and paracetamol, alongside triptans for moderate to severe attacks, per the same Neurology India review. These are inexpensive, widely stocked, and effectively uninsured-but-unnecessary given their low cost.

Migraine itself is not a rare condition in India. The Global Burden of Disease study identified headache disorders as the country's most prevalent neurological condition, with migraine alone accounting for an estimated 213.9 million cases, according to figures cited in the same Neurology India analysis. At that population scale, a coverage gap on newer drug classes is a systemic access issue, not an edge case.

What does this mean for a hospital's own pharmacy and OPD setup?

Since almost none of migraine's actual drug spend routes through hospitalisation-based migraine insurance, the entire financial relationship between a hospital and a migraine patient runs through the OPD pharmacy counter, cash or a modest OPD rider, not through a claims desk. A hospital's in-house pharmacy either fills that prescription reliably at the point of consultation, or the patient walks it to whichever outside chemist is cheapest that week.

For a high-frequency, chronic OPD condition like migraine, that walked-out prescription is a repeat loss every single month a refill is due, not a one-time miss. Our managed hospital pharmacy services piece covers how in-house OPD pharmacy stocking is built to hold onto exactly this kind of recurring, cash-and-carry prescription base, and our prescription leakage piece covers what that repeat leakage adds up to across a hospital's OPD volume.

Sources

1. 1National Health Benefit Package 2.2 — National Health Authority, Government of India
2. 2FAQs on Health Insurance Regulations — Insurance Regulatory and Development Authority of India
3. 3The Treatment Profile of Migraine in India: A Glimpse of Current Practice — Neurology India, 2025
4. 4Practice-Based Consensus Amongst Indian Neurologists on Migraine Management — PMC, National Institutes of Health
5. 5Press Information Bureau: National Health Authority revises Health Benefit Package of PM-JAY — Government of India

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical or insurance advice. Coverage terms vary by insurer and policy; verify current terms directly with the insurer or IRDAI before relying on any figure here.